AI just outdiagnosed your attending, biosimilars are rewriting drug economics, and independent pharmacy is being rebuilt.
The data is in: Are you ready to act?
In healthcare, some signals are too strong to ignore. Over the past year, three breakthroughs have landed like thunderclaps, each carrying a message for every pharmacist and healthcare professional willing to listen.
Signal 1: AI just outdiagnosed your attending, and the data is no longer deniable
Let’s start with the signal that’s impossible to ignore. In July 2025, a landmark study published in partnership with Microsoft Research put an AI diagnostic system powered by OpenAI’s o3 model head-to-head against 21 seasoned physicians from the US and UK. The AI correctly diagnosed 85.5% of real world NEJM cases, that’s four times more accurate than the doctors, who had up to 20 years’ experience.
If that’s not enough, another UVA Health study found ChatGPT alone hit a median diagnostic accuracy north of 92%. Physicians using ChatGPT, meanwhile, scored 76%. With conventional tools, accuracy dropped to 74%. The kicker? The AI needed fewer tests to reach its conclusions.
The take home is clear: AI isn’t just “assisting” doctors anymore. In controlled scenarios, it’s outperforming them.
But this doesn’t mean replacing clinical judgment. The real value comes when clinicians learn to use these tools effectively, to ask better questions, catch rare presentations, and flag complex drug-disease interactions. The pharmacist who understands how to prompt AI, interpret its output, and apply it judiciously will bring a level of reasoning and efficiency others simply can’t match.
Reflect: Are you building your AI literacy, or waiting to be caught off guard?
Signal 2: Biosimilars just generated $20 billion in savings, and 90% of the next wave has no competition
While headlines focused on soaring drug costs, biosimilars quietly saved the US healthcare system $20.2 billion in 2024 alone. That’s not just economic theory, it translated into 460 million extra days of therapy for real patients.
Yet here’s the signal most missed: Of 118 biologics losing exclusivity over the next decade (worth $234 billion in annual sales), 90% have no biosimilars in the pipeline. That “biosimilar void” is both a warning and an opportunity.
The biologics that do have biosimilars, like Stelara and Xolair, are creating dramatic access shifts. Some biosimilars now cost 90% less than the original. Where pharmacist substitution laws allow it, these drugs can be swapped in without physician approval.
This puts pharmacists at a crossroads: Those who know their state’s biosimilar laws, who track interchangeability status, and who guide patients through support programs are becoming indispensable. They’re not just matching drugs to scripts; they’re shaping billions in drug spending and unlocking access for patients who would otherwise go without.
Ask yourself: Are you ready for the next wave of biosimilars, or will your patients, and your practice, get left behind?
Signal 3: The PBM model is breaking, and independent pharmacy is being rebuilt around clinical value
In August 2025, retail giant Walgreens was bought for $23.7 billion and immediately began closing stores and slashing thousands of jobs. But the real story is happening outside the headlines: independent pharmacies are shifting from “pill counters” to clinical care centers.
The old retail model, built on dispensing volume, is collapsing under unsustainable fees and reimbursement cuts. Surviving pharmacies are those that deliver clinical services, medication management, chronic disease care, digital adherence support, and partner with primary care and payers to deliver outcomes, not just fill bottles.
The message is simple: If your identity as a pharmacist is tied to dispensing, your future is vulnerable. But if you’re leading with clinical expertise and outcomes, you’re exactly what the next decade of healthcare needs.
Consider: Where does your value come from, the drug, or the difference you make in patient care?
What happens next, and why it’s your move
These three signals aren’t predictions. They’re realities unfolding now. AI is setting new bars for diagnostic accuracy. Biosimilars are opening and closing doors in drug economics. Pharmacies are being forced to decide whether to double down on the past or build on clinical value.
As a pharmacist, you have a choice: Wait and react, or learn, adapt, and lead.
So I’ll leave you with this:
- How are you investing in your AI and biosimilar knowledge?
- What clinical skills are you developing to stay indispensable?
- Which side of pharmacy’s future will you be on?
Stay ahead of healthcare shifts, clinical innovation, and future of Pharmacy
